metricas

Medicina Clínica

Sugerencias
Medicina Clínica Cardiovascular risk assessment in inflammatory bowel disease with metabolic dysf...
Información de la revista
Vol. 162. Núm. 9.
Páginas e25-e40 Páginas 409-460 (Mayo 2024)
Cita
Cita
Compartir
Descargar PDF
Más opciones de artículo
Visitas
664
Vol. 162. Núm. 9.
Páginas e25-e40 Páginas 409-460 (Mayo 2024)
Original article

Cardiovascular risk assessment in inflammatory bowel disease with metabolic dysfunction-associated steatotic liver disease

Evaluación del riesgo cardiovascular en la enfermedad inflamatoria intestinal asociada a la enfermedad hepática grasa metabólica
Visitas
664
Sandra García-Mateoa,b,1,
Autor para correspondencia
sgarciamateo7@gmail.com

Corresponding author.
, Samuel J. Martínez-Domíngueza,b,1, Carla J. Gargallo-Puyueloa,b, Beatriz Gallegob, Erika Alfambrab, María C. Asoa,b, Neus Martinez-Micaeloc, Nuria Amigóc,d, Javier Martínez-Garcíab,e, Pedro M. Baptistab,f, Borja Sanzg, Sara Ballestah, Judith Espinosah, Carlos Tejeroh, Fernando Gomollóna,c
a Department of Gastroenterology, “Lozano Blesa” University Clinical Hospital, 50009 Zaragoza, Spain
b Aragón Health Research Institute (IIS Aragón), 50009 Zaragoza, Spain
c School of Medicine, University of Zaragoza, 50009 Zaragoza, Spain
d Biosfer Teslab, Plaça del Prim 10, 2on 5a, 43201 Reus, Spain
e University of Zaragoza, Department of Multiscale in Mechanical and Biological Engineering, Spain
f CIBER Enfermedades Hepáticas y Digestivas (CIBERehd), 28029 Madrid, Spain
g Department of Endocrinology, Manises Hospital, 46940 Valencia, Spain
h Department of Neurology, Lozano Blesa University Hospital, 50009 Zaragoza, Spain
Este artículo ha recibido
Información del artículo
Resumen
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Abstract
Background and aims

Inflammatory bowel disease (IBD) has been reported to increase the risk of early atherosclerosis even in young patients. Moreover, metabolic dysfunction-associated steatotic liver disease (MASLD), which has been linked to IBD, is a well-recognized but underdiagnosis entity related to cardiovascular risk. We analyze the impact of MASLD in IBD patients’ cardiovascular risk through both advanced lipoprotein profile sorted by nuclear magnetic resonance spectroscopy, and carotid artery intima-media thickness (CIMT).

Methods

Cross-sectional cohort study which involves 941 IBD adult outpatients. Of them, 50 patients with IBD who met criteria for MASLD and 50 with IBD without MASLD, matched by sex and age were included. Alterations in CIMT were evaluated considering abnormal measures above the 75th percentile adjusted for sex and age. Specific advanced lipoprotein profile was also carried out.

Results

Most of the patients had an abnormal CIMT (58%). MASLD (OR=5.05, CI 95%=1.71–14.92) and female sex (OR=3.32, CI 95%=1.03–10) were significantly associated with CIMT alterations. Dense LDL particles (with high cholesterol composition in general cohort (OR=3.62, 95% CI=1.07–12.19) and high triglycerides density in young subgroup (OR=6.25, 95% CI=1.04–50) but not total LDL cholesterol were associated with CIMT alterations.

Conclusions

MASLD and female sex are associated with early atherosclerosis in IBD patients. Dense LDL particle in combination with vascular imaging findings should be evaluated as non-invasive tools in the management of cardiovascular risk in IBD patients.

Keywords:
Inflammatory bowel disease
Metabolic disfunction-associated steatotic liver disease
Cardiovascular risk
Carotid artery intima-media thickness
Dense LDL
Resumen
Antecedentes y objetivos

Se ha descrito que la enfermedad inflamatoria intestinal (EII) incrementa el riesgo de aterosclerosis precoz incluso en pacientes jóvenes. Además, la esteatosis hepática metabólica (MASLD), entidad relacionada con la EII, es una causa reconocida pero infradiagnosticada de riesgo cardiovascular. Hemos analizado el impacto de MASLD en el desarrollo de enfermedades cardiovasculares en los pacientes con EII a través de un estudio avanzado del perfil de lipoproteínas con espectroscopia por resonancia magnética nuclear y el grosor íntima-media carotídeo (GIMc).

Métodos

Se trata de un estudio de cohortes transversal de 941 pacientes ambulatorios con EII. De ellos, se incluyeron 50 con EII que cumplían criterios de MASLD y otros 50 con EII sin MASLD emparejados por sexo y edad. Se evaluaron las alteraciones de GIMc considerando patológicos aquellos valores por encima del percentil 75 ajustado por sexo y edad. Se analizó también el perfil avanzado de lipoproteínas.

Resultados

Muchos de los pacientes tuvieron un GIMc alterado (58%). La presencia de MASLD (odds ratio [OR]=5,05, intervalo de confianza [IC] 95%=1,71-14,92) y el sexo femenino (OR=3,32, IC 95%=1,03-10), se asociaron significativamente a las alteraciones de GIMc. Las partículas de baja densidad (LDL) (con alta concentración de colesterol en la cohorte general [OR=3,62, IC 95%=1,07-12,19], así como de de triglicéridos en el subgrupo de pacientes jóvenes [OR=6,25, IC 95%=1,04-50]), pero no las cifras de colesterol LDL total, se asociaron a alteraciones en el GIMc.

Conclusiones

La presencia de MASLD y el sexo femenino se asocian a aterosclerosis precoz en los pacientes con EII. El estudio de las partículas LDL densas en combinación con los hallazgos en las pruebas de imagen vascular, deberían valorarse como herramientas no invasivas de detección de riesgo cardiovascular en los sujetos con EII.

Palabras clave:
Enfermedad inflamatoria intestinal
Enfermedad hepática esteatósica asociada a disfunción metabólica
Riesgo cardiovascular
Grosor íntima-media carotídeo
Partículas de baja densidad

Artículo

Opciones para acceder a los textos completos de la publicación Medicina Clínica
Suscriptor
Suscriptor de la revista

Si ya tiene sus datos de acceso, clique aquí.

Si olvidó su clave de acceso puede recuperarla clicando aquí y seleccionando la opción "He olvidado mi contraseña".
Comprar
Comprar acceso al artículo

Comprando el artículo el PDF del mismo podrá ser descargado

Comprar ahora
Contactar
Teléfono para suscripciones e incidencias
De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h
Llamadas desde España
932 415 960
Llamadas desde fuera de España
+34 932 415 960
E-mail
References
[1]
M. Argollo, D. Gilardi, C. Peyrin-Biroulet, J.F. Chabot, L. Peyrin-Biroulet, S. Danese.
Comorbidities in inflammatory bowel disease: a call for action.
Lancet Gastroenterol Hepatol, 4 (2019), pp. 643-654
[2]
J. Kirchgesner, L. Beaugerie, F. Carrat, N.N. Andersen, T. Jess, M. Schwarzinger, et al.
Increased risk of acute arterial events in young patients and severely active IBD: a nationwide French cohort study.
[3]
M.E. Rinella, J.V. Lazarus, V. Ratziu, S.M. Francque, A.J. Sanyal, F. Kanwal, et al.
A multi-society Delphi consensus statement on new fatty liver disease nomenclature.
[4]
T.C. Liu, T.S. Stappenbeck.
Genetics and pathogenesis of inflammatory bowel disease.
Annu Rev Pathol, 11 (2016), pp. 127-148
[5]
A.C. Finney, S. Das, D. Kumar, M.P. McKinney, B. Cai, A. Yurdagul, et al.
The interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease.
Front Cardiovasc Med, 10 (2023), pp. 1116861
[6]
A. Sachdeva, C.P. Cannon, P.C. Deedwania, K.A. LaBresh, S.C. Smith, D. Dai, et al.
Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines.
Am Heart J, 157 (2009), pp. 111-117
[7]
E. Myasoedova, C.S. Crowson, H.M. Kremers, V.L. Roger, P.D. Fitz-Gibbon, T.M. Therneau, et al.
Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease.
Ann Rheum Dis, 70 (2011), pp. 482-487
[8]
D.M. Schulte, K. Paulsen, K. Türk, B. Brandt, S. Freitag-Wolf, I. Hagen, et al.
Small dense LDL cholesterol in human subjects with different chronic inflammatory diseases.
Nutr Metab Cardiovasc Dis, 28 (2018), pp. 1100-1105
[9]
L. Tokgozoglu, D.A. Morrow, S.J. Nicholls.
Great debate: lipid-lowering therapies should be guided by vascular imaging rather than by circulating biomarkers.
Eur Heart J, 44 (2023), pp. 2292-2304
[10]
R.B. Biondi, P.S. Salmazo, S.G.Z. Bazan, J.C. Hueb, S.A.R. de Paiva, L.Y. Sassaki.
Cardiovascular risk in individuals with inflammatory bowel disease.
Clin Exp Gastroenterol, 13 (2020), pp. 107-113
[11]
U. Näslund, N. Ng, A. Lundgren, E. Fhärm, C. Grönlund, H. Johansson, et al.
Visualization of asymptomatic atherosclerotic disease for optimum cardiovascular prevention (VIPVIZA): a pragmatic, open-label, randomised controlled trial.
[12]
E. Gómez-gracia, V. Ruiz-gutiérrez, M. Fiol.
Primary prevention of cardiovascular disease with a mediterranean diet.
N Engl J Med, 378 (2018), pp. e34
[13]
P.D. Jones, M.D. Kappelman, C.F. Martin, W. Chen, R.S. Sandler, M.D. Long.
Exercise decreases risk of future active disease in patients with inflammatory bowel disease in remission.
Inflamm Bowel Dis, 21 (2015), pp. 1063-1071
[14]
F. Gomollón, A. Dignass, V. Annese, H. Tilg, G. Van Assche, J.O. Lindsay, et al.
3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: Part 1: Diagnosis and medical management.
J Crohns Colitis, 11 (2017), pp. 3-25
[15]
H. Tilg, M. Effenberger.
From NAFLD to MAFLD: when pathophysiology succeeds.
Nat Rev Gastroenterol Hepatol, 17 (2020), pp. 387-388
[16]
P.J. Touboul, M.G. Hennerici, S. Meairs, H. Adams, P. Amarenco, N. Bornstein, et al.
Mannheim carotid intima-media thickness and plaque consensus (2004–2006–2011): an update.
Cerebrovasc Dis, 34 (2012), pp. 290-296
[17]
J.H. Stein, C.E. Korcarz, R.T. Hurst, E. Lonn, C.B. Kendall, E.R. Mohler, et al.
Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of echocardiography carotid intima-media thickness task force endorsed by the society for vascular medicine.
J Am Soc Echocardiogr, 21 (2008), pp. 93-111
[18]
SCORE2 working group and ESC Cardiovascular risk collaboration.
SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe.
Eur Heart J, 42 (2021), pp. 2439-2454
[19]
G. Pichler, N. Amigo, M. Tellez-Plaza, M.A. Pardo-Cea, A. Dominguez-Lucas, V.G. Marrachelli, et al.
LDL particle size and composition and incident cardiovascular disease in a South-European population: the Hortega-Liposcale follow-up study.
Int J Cardiol, 264 (2018), pp. 172-178
[20]
S.A. Kim, S.H. Park, S.H. Jo, K.H. Park, H.S. Kim, S.J. Han, et al.
Alterations of carotid arterial mechanics preceding the wall thickening in patients with hypertension.
Atherosclerosis, 248 (2016), pp. 84-90
[21]
J. Sun, J. Halfvarson, P. Appelros, D. Bergman, F. Ebrahimi, B. Roelstraete, et al.
Long-term risk of stroke in patients with inflammatory bowel disease: a population-based, sibling-controlled cohort study, 1969–2019.
Neurology, 101 (2023), pp. e653-e664
[22]
H. Wu, M. Xu, H. Hao, M.A. Hill, C. Xu, Z. Liu.
Endothelial dysfunction and arterial stiffness in patients with inflammatory bowel disease: a systematic review and meta-analysis.
J Clin Med, 11 (2022), pp. 3179
[23]
V. Bruzzese, G. Palermo, L. Ridola, R. Lorenzetti, C. Hassan, A. Izzo, et al.
Preclinical atherosclerosis in patients with inflammatory bowel diseases: a case–control study.
Ann Transl Med, 5 (2017), pp. 158
[24]
A. Bigeh, A. Sanchez, C. Maestas, M. Gulati.
Inflammatory bowel disease and the risk for cardiovascular disease: does all inflammation lead to heart disease?.
Trends Cardiovasc Med, 30 (2020), pp. 463-469
[25]
X. Wang, R. Zhang, S. Man, J. Lv, C. Yu, J. Yin, et al.
Metabolic-associated fatty liver disease in relation to site-specific and multiple-site subclinical atherosclerosis.
Liver Int, 43 (2023), pp. 1691-1698
[26]
L.J. Shaw, R. Bugiardini, C.N. Bairey Merz.
Women and ischemic heart disease: evolving knowledge.
J Am Coll Cardiol, 54 (2009), pp. 1561-1575
[27]
M. Romero-Gómez, S. Zelber-Sagi, M. Trenell.
Treatment of NAFLD with diet, physical activity and exercise.
J Hepatol, 67 (2017), pp. 829-846
[28]
M.H. Kim, J.H. Sung, M.N. Jin, E. Jang, H.T. Yu, T.H. Kim, et al.
Impact of physical activity on all-cause mortality according to specific cardiovascular disease.
Front Cardiovasc Med, 9 (2022), pp. 811058
[29]
N. Zmora, J. Suez, E. Elinav.
You are what you eat: diet, health and the gut microbiota.
Nat Rev Gastroenterol Hepatol, 16 (2019), pp. 35-56
[30]
A. Hernández-Camba, M. Carrillo-Palau, L. Ramos, N.H. Alvarez-Buylla, I. Alonso-Abreu, A. Hernández-Pérez, et al.
Carotid plaque assessment reclassifies patients with inflammatory bowel disease into very-high cardiovascular risk.
J Clin Med, 10 (2021), pp. 1671
asdasdasd
Opciones de artículo
Herramientas
Material suplementario